185 related articles for article (PubMed ID: 35150246)
1. Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.
Volkmann ER; Kreuter M; Hoffmann-Vold AM; Wijsenbeek M; Smith V; Khanna D; Denton CP; Wuyts WA; Miede C; Alves M; Sambevski S; Allanore Y
Rheumatology (Oxford); 2022 Nov; 61(11):4397-4408. PubMed ID: 35150246
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
3. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects.
Maher TM; Bourdin A; Volkmann ER; Vettori S; Distler JHW; Alves M; Stock C; Distler O
Respir Res; 2022 Jul; 23(1):178. PubMed ID: 35790961
[TBL] [Abstract][Full Text] [Related]
4. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease.
Allanore Y; Khanna D; Smith V; Aringer M; Hoffmann-Vold AM; Kuwana M; Merkel PA; Stock C; Sambevski S; Denton CP;
Rheumatology (Oxford); 2024 Mar; 63(3):639-647. PubMed ID: 37294870
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
Kuwana M; Allanore Y; Denton CP; Distler JHW; Steen V; Khanna D; Matucci-Cerinic M; Mayes MD; Volkmann ER; Miede C; Gahlemann M; Quaresma M; Alves M; Distler O
Arthritis Rheumatol; 2022 Mar; 74(3):518-526. PubMed ID: 34514739
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial.
Azuma A; Chung L; Behera D; Chung M; Kondoh Y; Ogura T; Okamoto M; Swarnakar R; Zeng X; Zou H; Meng X; Gahlemann M; Alves M; Kuwana M;
Respir Investig; 2021 Mar; 59(2):252-259. PubMed ID: 33223487
[TBL] [Abstract][Full Text] [Related]
7. Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial.
Denton CP; Goh NS; Humphries SM; Maher TM; Spiera R; Devaraj A; Ho L; Stock C; Erhardt E; Alves M; Wells AU
Rheumatology (Oxford); 2023 May; 62(5):1870-1876. PubMed ID: 36111858
[TBL] [Abstract][Full Text] [Related]
8. Interstitial lung disease in patients with systemic sclerosis: what can we learn from the SENSCIS trial?
Assassi S; Tumuluri S; Levin RW
Clin Exp Rheumatol; 2023 Aug; 41(8):1713-1719. PubMed ID: 37534955
[TBL] [Abstract][Full Text] [Related]
9. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
[TBL] [Abstract][Full Text] [Related]
10. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.
Kreuter M; Del Galdo F; Miede C; Khanna D; Wuyts WA; Hummers LK; Alves M; Schoof N; Stock C; Allanore Y
Arthritis Res Ther; 2022 Jan; 24(1):19. PubMed ID: 35012623
[TBL] [Abstract][Full Text] [Related]
11. Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease.
Kreuter M; Hoffmann-Vold AM; Matucci-Cerinic M; Saketkoo LA; Highland KB; Wilson H; Alves M; Erhardt E; Schoof N; Maher TM
Rheumatology (Oxford); 2023 Feb; 62(SI):SI43-SI53. PubMed ID: 35640959
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial.
Kuwana M; Ogura T; Makino S; Homma S; Kondoh Y; Saito A; Ugai H; Gahlemann M; Takehara K; Azuma A
Mod Rheumatol; 2021 Jan; 31(1):141-150. PubMed ID: 32243207
[TBL] [Abstract][Full Text] [Related]
13. Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression.
Khanna D; Maher TM; Volkmann ER; Allanore Y; Smith V; Assassi S; Kreuter M; Hoffmann-Vold AM; Kuwana M; Stock C; Alves M; Sambevski S; Denton CP
RMD Open; 2023 Feb; 9(1):. PubMed ID: 36796874
[TBL] [Abstract][Full Text] [Related]
14. Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial.
Maher TM; Mayes MD; Kreuter M; Volkmann ER; Aringer M; Castellvi I; Cutolo M; Stock C; Schoof N; Alves M; Raghu G;
Arthritis Rheumatol; 2021 Apr; 73(4):671-676. PubMed ID: 33142016
[TBL] [Abstract][Full Text] [Related]
15. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON.
Allanore Y; Vonk MC; Distler O; Azuma A; Mayes MD; Gahlemann M; James A; Kohlbrenner V; Alves M; Khanna D; Highland KB;
Ann Rheum Dis; 2022 Dec; 81(12):1722-1729. PubMed ID: 35973804
[TBL] [Abstract][Full Text] [Related]
16. Risk of Malnutrition in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease Treated With Nintedanib in the Randomized, Placebo-Controlled SENSCIS Trial.
Volkmann ER; McMahan ZH; Smith V; Jouneau S; Miede C; Alves M; Herrick AL;
Arthritis Care Res (Hoboken); 2023 Dec; 75(12):2501-2507. PubMed ID: 37357024
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
[TBL] [Abstract][Full Text] [Related]
18. Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics.
Kolb M; Flaherty KR; Silva RS; Prasse A; Vancheri C; Mueller H; Sroka-Saidi K; Wells AU;
Adv Ther; 2023 Dec; 40(12):5536-5546. PubMed ID: 37751022
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
Seibold JR; Maher TM; Highland KB; Assassi S; Azuma A; Hummers LK; Costabel U; von Wangenheim U; Kohlbrenner V; Gahlemann M; Alves M; Distler O;
Ann Rheum Dis; 2020 Nov; 79(11):1478-1484. PubMed ID: 32759258
[TBL] [Abstract][Full Text] [Related]
20. Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases.
Bonella F; Cottin V; Valenzuela C; Wijsenbeek M; Voss F; Rohr KB; Stowasser S; Maher TM
Adv Ther; 2022 Jul; 39(7):3392-3402. PubMed ID: 35576048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
